Thrombotic thrombocytopenic purpura (TTP)
Also known as: Thrombotic thrombocytopenic purpura
Methodology & AI Transparency ⓘ
Thrombotic thrombocytopenic purpura (TTP) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Thrombotic thrombocytopenic purpura (TTP) (also termed Thrombotic thrombocytopenic purpura) (M31.19; Osteoarthritis, Gout & Joint Pain) utilize urate-lowering titration [Thrombotic thrombocytopenic purpura (TTP) M31.19] and objective Serum Uric Acid in Thrombotic thrombocytopenic purpura (TTP) (M31.19: (Gout Target)) targets (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.19)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Synonyms for Thrombotic thrombocytopenic purpura (TTP) (M31.19): Thrombotic thrombocytopenic purpura (Arthritis & Joints).
- 3 Typical cash cost range: Differential triage of Thrombotic thrombocytopenic purpura (TTP) (M31.19) utilizes urate-lowering titration [Thrombotic thrombocytopenic purpura (TTP) M31.19].
- 4 Top reported side effects / signs: Objective lab/clinical target for Thrombotic thrombocytopenic purpura (TTP): Serum Uric Acid in Thrombotic thrombocytopenic purpura (TTP) (M31.19: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.19)) and hs-CRP & Erythrocyte in Thrombotic thrombocytopenic purpura (TTP) (M31.19: Sedimentation Rate).
Ask our AI Specialists anything about Thrombotic thrombocytopenic purpura (TTP)
What Is Thrombotic thrombocytopenic purpura (TTP)?
Physicians managing Thrombotic thrombocytopenic purpura (TTP) (also termed Thrombotic thrombocytopenic purpura) (M31.19; Osteoarthritis, Gout & Joint Pain) utilize urate-lowering titration [Thrombotic thrombocytopenic purpura (TTP) M31.19] and objective Serum Uric Acid in Thrombotic thrombocytopenic purpura (TTP) (M31.19: (Gout Target)) targets (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.19)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Thrombotic thrombocytopenic purpura (TTP) (ICD-10 M31.19) is driven by articular hyaline cartilage in Thrombotic thrombocytopenic purpura (TTP) (M31.19: proteoglycan degradation); specialists in Osteoarthritis, Gout & Joint Pain monitor hs-CRP & Erythrocyte in Thrombotic thrombocytopenic purpura (TTP) (M31.19: Sedimentation Rate) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Thrombotic thrombocytopenic purpura (TTP) (M31.19): activity-related deep aching in Thrombotic thrombocytopenic purpura (TTP) (M31.19: joint pain in)
- • Secondary Thrombotic thrombocytopenic purpura (TTP) clinical sign: brief morning joint in Thrombotic thrombocytopenic purpura (TTP) (M31.19: stiffness)
- • Symptom flares in Thrombotic thrombocytopenic purpura (TTP) correlating with Serum Uric Acid in Thrombotic thrombocytopenic purpura (TTP) (M31.19: (Gout Target)) deviation outside < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.19)
- • Functional arthritis & joints impact requiring urate-lowering titration [Thrombotic thrombocytopenic purpura (TTP) M31.19] evaluation (M31.19)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Thrombotic thrombocytopenic purpura (TTP) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M31.19 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Uric Acid in Thrombotic thrombocytopenic purpura (TTP) (M31.19: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.19) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Thrombotic thrombocytopenic purpura (TTP) (M31.19: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M31.19) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Thrombotic thrombocytopenic purpura (TTP) M31.19] | Preserved joint-space width (M31.19) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Thrombotic thrombocytopenic purpura (TTP)
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Thrombotic thrombocytopenic purpura (TTP))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Laboratory markers predicting tofacitinib efficacy in Japanese patients with: What a 467-Participant Study Found Changes in laboratory parameters at M1 could potentially be used to assess whether tofacitinib therapy will be effective at M3; however, further investigation is needed. Modern rheumatology • 2025-04-08 • Phase III Randomized Trial | N = 467 | 93/100 | PMID 39657989 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients We observed a risk reduction of 5% with prasugrel vs clopidogrel, indicating comparable efficacy. Journal of atherosclerosis and thrombosis • 2023-03-01 • Phase III Randomized Trial | N = 118 | 88/100 | PMID 35599000 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms, HRQOL, and work productivity up to 1 year in bDMARD-naïve and TNFi-IR patients with active PsA. The Journal of rheumatology • 2025-05-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39892885 ↗ |
Thrombotic thrombocytopenic purpura (TTP) Patient Community & “People Like Me” Threads
Filter Thrombotic thrombocytopenic purpura (TTP) community threads and patient logs by age, biological sex, dosage, and treatment duration.